MEK inhibition in combination with PI3K/AKT/MTOR is a promising therapeutic in basal bladder cancer.

被引：0
|
作者：
Apfel, Athena M. [1 ]
Merrill, Nathan M. [1 ]
Vandecan, Nathalie M. [1 ]
Bao, Liwei [1 ]
Cheng, Xu [1 ]
Lopez-Barcons, Lluis A. [1 ]
Day, Kathleen C. [1 ]
Palmbos, Phillip L. [1 ]
Day, Mark L. [1 ]
Udager, Aaron M. [1 ]
Soellner, Matthew B. [1 ]
Merajver, Sofia D. [1 ]
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1194
引用
收藏
页数：1
相关论文
共 50 条
  • [31] EGFR inhibition in combination with PI3K/AKT/mTOR and/or Bcl-2 inhibition is a promising novel therapeutic approach for inverted sinonasal papillomas and associated sinonasal carcinomas
    Apfel, Athena M.
    Qin, Zhaoping
    Liu, Albert
    Soellner, Matthew B.
    Merajver, Sofia D.
    Udager, Aaron M.
    Merrill, Nathan M.
    CANCER RESEARCH, 2022, 82 (12)
  • [32] Inhibition of PI3K/Akt/mTOR Signaling by Natural Products
    Huang, Shile
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2013, 13 (07) : 967 - 970
  • [33] The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
    Haagensen, E. J.
    Kyle, S.
    Beale, G. S.
    Maxwell, R. J.
    Newell, D. R.
    BRITISH JOURNAL OF CANCER, 2012, 106 (08) : 1386 - 1394
  • [34] Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer
    Butler, Dominika E.
    Marlein, Christopher
    Walker, Hannah F.
    Frame, Fiona M.
    Mann, Vincent M.
    Simms, Matthew S.
    Davies, Barry R.
    Collins, Anne T.
    Maitland, Norman J.
    ONCOTARGET, 2017, 8 (34) : 56698 - 56713
  • [35] The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress
    Bahrami, Afsane
    Khazaei, Majid
    Shahidsales, Soodabeh
    Hassanian, Seyed Mahdi
    Hasanzadeh, Malihe
    Maftouh, Mina
    Ferns, Gordon A.
    Avan, Amir
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2018, 119 (01) : 213 - 222
  • [36] Dual inhibition of MEK/MAPK and PI3K/Akt in multiple myeloma
    Steinbrunn, T.
    Stuehmer, T.
    Sayehli, C.
    Chatterjee, M.
    Einsele, H.
    Bargou, R. C.
    ONKOLOGIE, 2012, 35 : 140 - 140
  • [37] PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy
    Gloria Irene Manfredi
    Alessandra Dicitore
    Germano Gaudenzi
    Michele Caraglia
    Luca Persani
    Giovanni Vitale
    Endocrine, 2015, 48 : 363 - 370
  • [38] Targeting the PI3K/AKT/mTOR pathway in lung cancer: mechanisms and therapeutic targeting
    Qiang, Min
    Chen, Zhe
    Liu, Hongyang
    Dong, Junxue
    Gong, Kejian
    Zhang, Xinjun
    Huo, Peng
    Zhu, Jingjun
    Shao, Yifeng
    Ma, Jinazun
    Zhang, Bowei
    Liu, Wei
    Tang, Mingbo
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [39] Molecular Alterations of PI3K/Akt/mTOR Pathway: A Therapeutic Target in Endometrial Cancer
    Pavlidou, Athanasia
    Vlahos, Nikos F.
    SCIENTIFIC WORLD JOURNAL, 2014,
  • [40] Study of PI3K/AKT/mTor pathway in urothelial bladder carcinoma
    Saetta, A.
    Prekete, N.
    Trigka, E.
    Levidou, G.
    Karlou, M.
    Pavlopoulos, P.
    Korkolopoulou, P.
    Patsouris, E.
    VIRCHOWS ARCHIV, 2012, 461 : S170 - S170
12345